Skip to main content
. Author manuscript; available in PMC: 2011 Aug 1.
Published in final edited form as: Hypertension. 2010 Jun 14;56(2):297–303. doi: 10.1161/HYPERTENSIONAHA.110.150409

Figure 1. ICV minocycline attenuates Ang II-induced cardiovascular effects.

Figure 1

(a) Outline of experimental protocol. (b) Minocycline abolishes Ang II-induced hypertension. * P<0.05, † P<0.01 vs. the other three groups at the same time points. (c) Minocycline infusion attenuates cardiac hypertrophy induced by Ang II. Bar graphs are mean ± SEM of HW/BW ratio following each treatment (n=6 in each group). * P<0.05 vs. other three groups. Mino: minocycline. (d) Minocycline inhibits the increase in plasma NE induced by Ang II infusion. * P<0.05 vs. control; † P<0.05 vs. Ang II by one-way ANOVA followed by Bonferoni. (Control n=5; n=6 in the other three groups)